Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: Relationship with B-cell kinetics

Rheumatology

Volumn 51, Issue 5, 2012, Pages 833-840

  De la torre, Inmaculada ^a,b   Leandro, Maria J ^a   Valor, Lara ^a,b   Becerra, Elena ^a,b   Edwards, Jonathan C W ^a   Cambridge, Geraldine ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

B cell depletion; CD19 + B cells; Immunoglobulins; Rheumatoid arthritis; Rituximab

Indexed keywords

CD19 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE DEPLETION; CELL COUNT; CELL SELECTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RELAPSE; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULINS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED;

EID: 84860229721     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker417     Document Type: Article

References (35)

1. Edwards JC, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 1998;37:126-30.
2. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
3. Leandro MJ, Cambridge G, Ehrenstein MR et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20.
4. Popa C, Leandro MJ, Cambridge G et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology 2007;46:626-30.
5. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237:264-83.
6. Hiepe F, Dörner T, Hauser AE et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011;7:170-8.
7. Roll P, Dörner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008;58:1566-75.
8. Dass S, Rawstron AC, Vital EM et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008;58:2993-9.
9. Möller B, Aeberli D, Eggli S et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther 2009;11:R62.
10. Thurlings RM, Vos K, Wijbrandts CA et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67:917-25.
11. Thurlings RM, Teng O, Vos K et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:409-12.
12. Teng YK, Levarht EW, Hashemi M et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007;56:3909-18.
13. Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54.
14. van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67.
15. De La Torre I, Moura RA, Leandro MJ et al. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Ann Rheum Dis 2010;69:2181-8.
16. De La Torre I, Leandro MJ, Moura R et al. BAFF binding receptors (BBR) related to relapse after rituximab in patients with rheumatoid arthritis. Abstract 739. Arthritis Rheum 2010;62:S309.
17. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
18. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23(Suppl. 39):S93-9.
19. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-8.
20. Diwakar L, Gorrie S, Richter A et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 2010;63:275-7.
21. Nishio M, Endo T, Fujimoto K et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 2005;75: 527-9.
22. van Esser JW, Niesters HG, van der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-9.
23. Imashuku S, Teramura T, Morimoto A et al. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant 2004;33:129-30.
24. Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 2009;46:120-2.
25. Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006;38:433-6.
26. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777-83.
27. Lim SH, Zhang Y, Wang Z et al. Maintenance rituximab after autologus stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 2005;35: 207-8.
28. Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV related lymphoma. J Clin Oncol 2005;23:247-8.
29. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997;388:133-4.
30. Kutteh WH, Prince SJ, Phillips JO et al. Properties of immunoglobulin A in serum of individuals with liver diseases and in hepatic bile. Gastroenterology 1982;82: 184-93.
31. Avery DT, Kalled SL, Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003;112: 286-97.
32. Cambridge G, Stohl W, Leandro MJ et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-32.
33. Groom J, Mackay F. B cells flying solo. Immunol Cell Biol 2008;86:40-6.
34. Darce JR, Arendt BK, Wu X et al. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7276-86.
35. Rui L, Healy JI, Blasioli J et al. ERK signaling is a molecular switch integrating opposing inputs from B cell receptor and T cell cytokines to control TLR4-driven plasma cell differentiation. J Immunol 2006;177:5337-46.